Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. MicroRNAs and histone deacetylase inhibition-mediated protection against inflammatory β-cell damage

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Early life predictors of midlife allostatic load: A prospective cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Determination of anti-HCV and quantification of HCV-RNA and IP-10 from dried blood spots sent by regular mail

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Convergent validity of ActiGraph and Actical accelerometers for estimating physical activity in adults

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Determination of anti-HCV and quantification of HCV-RNA and IP-10 from dried blood spots sent by regular mail

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND AND AIMS: In the Nordic countries (Denmark, Finland, Iceland, Norway, Sweden), the prevalence of chronic hepatitis C virus (HCV) infection is relatively low in the general population, but is much higher among people who inject drugs (PWID). We conducted an exploratory study to investigate the extent to which these countries have policies supporting key elements of the public health response that is necessary to achieve the global goal of eliminating HCV as a public health threat.

METHODS: Fourteen stakeholders representing government agencies, medical societies, and civil society organisations (CSOs) in the Nordic countries completed a cross-sectional online survey that included 21 policy questions related to national coordination, prevention, testing, linkage to care, and treatment. We summarised the findings in a descriptive analysis, and noted discrepant responses from stakeholders within the same country.

RESULTS: Stakeholders reported that three of the five study countries have national viral hepatitis strategies, while only Iceland has a national HCV elimination goal. The availability of harm reduction services varies, with opioid substitution therapy provided for the general population throughout all countries, but not needle and syringe programmes. No country has access to anonymous HCV testing in all parts of the country. National HCV treatment guidelines are available in all countries except Finland, and all countries provide publicly funded direct-acting antiviral treatment. Disagreement regarding policies was observed across countries, and CSOs were the stakeholder group that most frequently answered survey questions incorrectly.

CONCLUSION: The Nordic region as a whole has not consistently expressed its commitment to tackling HCV, despite the existence of large HCV epidemics among PWID in these countries. Stakeholder alignment and an established elimination goal with an accompanying strategy and implementation plan should be recognised as the basis for coordinated national public health efforts to achieve HCV elimination in the Nordic region and elsewhere.

OriginalsprogEngelsk
TidsskriftP L o S One
Vol/bind13
Tidsskriftsnummer1
ISSN1932-6203
DOI
StatusUdgivet - 1 jan. 2018

ID: 52627044